Last updated on March 2019

A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

Brief description of study

This is a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of RO7105705 in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period will be available to participants who complete the double-blind treatment period and who, in the judgment of the investigator, would potentially benefit from open-label RO7105705 treatment.

Clinical Study Identifier: NCT03289143

Contact Investigators or Research Sites near you

Start Over

Reference Study ID: GN39763

Brain Matters Research, Inc.
Delray Beach, FL United States
  Connect »

Reference Study ID: GN39763

Florida Atlantic University; College of Medicine
Boca Raton, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.